home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408a.zip
/
M9480102.TXT
< prev
next >
Wrap
Text File
|
1994-08-09
|
3KB
|
44 lines
Document 0102
DOCN M9480102
TI HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse
transcriptase mutation and CD4 cell decline in zidovudine-treated
patients.
DT 9410
AU Kozal MJ; Shafer RW; Winters MA; Katzenstein DA; Aguiniga E; Halpern J;
Merigan TC; Center for AIDS Research, Stanford University Medical
Center,; California 94305.
SO J Acquir Immune Defic Syndr. 1994 Aug;7(8):832-8. Unique Identifier :
AIDSLINE MED/94293165
AB The variable rate of disease progression in HIV-1-infected patients
treated with zidovudine may be related to certain viral characteristics,
such as, antiviral drug resistance, virus burden, and viral
syncytium-inducing (SI) capacity. Thirty-two HIV-1-infected patients
treated with zidovudine (mean of 34 months) were studied to determine
the relationship of SI phenotype and the codon 215 pol gene mutation (a
marker of zidovudine resistance) to virus burden and CD4 cell decline.
Patients with SI strains and the codon 215 mutation in their proviral
DNA had a 54% decline in CD4 cells and a virus burden of 21,480 proviral
DNA copies/10(6) CD4 cells. In contrast, patients with non-SI (NSI)
strains and wild-type at codon 215 had a 10% increase in CD4 cells and
had a viral burden 1/46 that of patients with SI and the 215 mutation.
Among patients with NSI strains, changes in CD4 cells depended on the
presence of the codon 215 mutation (-160 CD4 cells/microliters),
compared with those wild-type at codon 215 (+28 CD4 cells/microliters)
(p < 0.01). There was a concordant rise in virus burden between proviral
DNA and plasma HIV RNA depending on HIV phenotype and genotype. Using
multiple linear regression, SI phenotype and the codon 215 mutation were
found to independently predict CD4 cell decline and increased virus
burden in zidovudine-treated patients.
DE Codon/CHEMISTRY Drug Resistance, Microbial/GENETICS DNA, Viral/BLOOD
Genotype Giant Cells/MICROBIOLOGY Human HIV Infections/*DRUG
THERAPY/IMMUNOLOGY/*MICROBIOLOGY HIV-1/DRUG
EFFECTS/GENETICS/*PHYSIOLOGY Leukocyte Count Leukocytes,
Mononuclear/MICROBIOLOGY Mutation Phenotype Proviruses/GENETICS
Regression Analysis Reverse Transcriptase/*GENETICS RNA,
Viral/BLOOD/GENETICS Support, U.S. Gov't, P.H.S. T4 Lymphocytes
Zidovudine/PHARMACOLOGY/*THERAPEUTIC USE JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).